Second DCIS Diagnoses May Not Be Related to Initial Lesion
DNA sequencing found that in many cases when DCIS recurred, the lesion was unrelated to the first diagnosis, raising questions about how to best treat recurrence.
Progress Against Cancer
DNA sequencing found that in many cases when DCIS recurred, the lesion was unrelated to the first diagnosis, raising questions about how to best treat recurrence.
An AACR Annual Meeting 2022 session highlights the impact of research advocacy partnerships for a variety of cancers.
In a 1735 letter to the citizens of Philadelphia about the need to tighten the city’s fire safety measures, Benjamin Franklin famously wrote, “An ounce of prevention is worth a pound of cure.” This...
Experts discuss shortcomings of current COVID-19 vaccines in people with cancer while highlighting possibilities of T-cell activation.
From the AACR Annual Meeting, “practice changing” immunotherapy effective against lung cancer, and CAR T-cell therapy targets solid tumors.
Excitement and emotion ran high Sunday morning as Margaret Foti, PhD, MD (hc), chief executive officer of the American Association for Cancer Research (AACR), officially launched the Annual Meeting 2022 Sunday in New Orleans....
CAR T-cell therapy approved for relapsed large B-cell lymphoma, and screening catches lung cancer earlier, although disparities persist
Chemo brain may provide clues for long-haul COVID-19, and researchers analyze relationship between obesity and cancer.
The FDA approved the cellular immunotherapy axicabtagene ciloleucel for second-line treatment of patients with large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved axicabtagene ciloleucel (Yescarta) for the treatment of adult...
In 2015, NFL running back Brandon Bolden was having an incredible season with the New England Patriots. That year, he helped his team to a Super Bowl win against the Seattle Seahawks. That...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More